Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-15-074427
Filing Date
2015-10-06
Accepted
2015-10-06 18:53:16
Documents
2
Period of Report
2015-10-06

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6165
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 3973
  Complete submission text file 0001209191-15-074427.txt   11472
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Issuer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 15 NEW ENGLAND EXECUTIVE PARK BURLINGTON MA 01803
Business Address
Walker Neal (Reporting) CIK: 0001604457 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37581 | Film No.: 151147479